Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited (HKSE: 3692) is trading at HK$33.52, about ₹411 at today's HKD/INR rate, as of 29 Sep 2026, 1:29 AM ET, up 0.36% today. Indian residents can buy Hansoh Pharmaceutical Group from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$33.16
Today's high
HK$33.98
52 week low
HK$28.06
52 week high
HK$44.22
3692 opened at HK$33.40, closed previously at HK$33.40, and has traded between HK$28.06 and HK$44.22 over the past 52 weeks.
About
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Key statistics
Avg. volume
12.09M
Market cap
HK$203.23B
P/E Ratio
26.01
Price-to-sales ratio
10.91
Enterprise value
CN¥173.03B
Free cash flow yield
3.49%
Debt-to-equity ratio
0.11
Return on equity
18.26%
ROIC
11.99%
Beta
0.56
Dividend yield
1.45%
Last dividend
HK$0.43
Financial overview
Revenue
CN¥15.03B
Earnings per share
CN¥0.93
Free cash flow
CN¥6.25B
Net profit margin
42.01%
Gross margin
90.47%
EBITDA
CN¥5.77B
Revenue growth
22.57%
Similar securities
This is not an investment recommendation
How to buy Hansoh Pharmaceutical Group from India
Indian residents can buy Hansoh Pharmaceutical Group shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Hansoh Pharmaceutical Group and place an order
Find Hansoh Pharmaceutical Group by name or by its ticker, 3692, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Hansoh Pharmaceutical Group trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Hansoh Pharmaceutical Group position in HKD and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.
Read the full guide: how to invest in Hansoh Pharmaceutical Group from India
Trading and taxes when buying Hansoh Pharmaceutical Group from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Hansoh Pharmaceutical Group’s current yield is 1.45%.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Hansoh Pharmaceutical Group stock?
Yes. Hansoh Pharmaceutical Group (3692) has been listed on the Hong Kong Stock Exchange since 2019, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Hansoh Pharmaceutical Group share cost in rupees?
One Hansoh Pharmaceutical Group share is HK$33.52 — about ₹411 at an HKD/INR rate of 12.25 on 28 Sep 2026. Both the Hansoh Pharmaceutical Group price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Hansoh Pharmaceutical Group from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Hansoh Pharmaceutical Group?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Hansoh Pharmaceutical Group shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Hansoh Pharmaceutical Group price. Paasa issues a capital-gains statement for your return.
Does Hansoh Pharmaceutical Group pay a dividend, and how is it taxed in India?
Yes. Hansoh Pharmaceutical Group pays a dividend and the current yield is 1.45%; the last declared dividend was HK$0.43 per share, about ₹5.29. Dividends are taxed at your slab rate in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.
When can I trade Hansoh Pharmaceutical Group from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Hansoh Pharmaceutical Group a Hong Kong SAR China company, and does that change how it is taxed?
Hansoh Pharmaceutical Group trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Hansoh Pharmaceutical Group trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Hansoh Pharmaceutical Group shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Hansoh Pharmaceutical Group holding, its cost and its closing value.
How do I sell Hansoh Pharmaceutical Group and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.